奥美拉唑用于提高伏立康唑亚治疗浓度以治疗曲霉菌感染。
Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
机构信息
Parkland Health and Hospital System, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2012 Nov;56(11):6001-2. doi: 10.1128/AAC.00700-12. Epub 2012 Aug 13.
Abstract
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole "boosting" effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.
摘要
伏立康唑是治疗曲霉菌感染的首选抗真菌药物。建议进行治疗药物监测以达到目标浓度并预防毒性。然而，药代动力学的可变性、细胞色素 P450 多态性和广泛的药物相互作用可能导致治疗浓度不足。我们报告了一例奥美拉唑增强伏立康唑作用的病例，该患者持续存在治疗谷浓度不足，使用奥美拉唑后达到了治疗曲霉菌的目标浓度。
相似文献
1
Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.奥美拉唑用于提高伏立康唑亚治疗浓度以治疗曲霉菌感染。
Antimicrob Agents Chemother. 2012 Nov;56(11):6001-2. doi: 10.1128/AAC.00700-12. Epub 2012 Aug 13.
2
Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.儿科造血干细胞移植患者伏立康唑血药浓度变化很大。
Antimicrob Agents Chemother. 2013 Jan;57(1):235-40. doi: 10.1128/AAC.01540-12. Epub 2012 Oct 31.
3
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.伏立康唑和泊沙康唑治疗侵袭性曲霉病的治疗药物监测。
Expert Rev Anti Infect Ther. 2013 Sep;11(9):931-41. doi: 10.1586/14787210.2013.826989.
4
Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.囊性纤维化患者口服伏立康唑的药代动力学
J Antimicrob Chemother. 2011 Oct;66(10):2438-40. doi: 10.1093/jac/dkr300. Epub 2011 Jul 25.
5
Voriconazole concentrations in synovial fluid and bone tissues.伏立康唑在滑液和骨组织中的浓度。
J Antimicrob Chemother. 2007 Apr;59(4):818-9. doi: 10.1093/jac/dkm023. Epub 2007 Feb 28.
6
Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.对一名患有侵袭性曲霉病且需要体外膜肺氧合的儿童进行伏立康唑治疗药物监测。
Ther Drug Monit. 2008 Dec;30(6):643-6. doi: 10.1097/FTD.0b013e3181898b0c.
7
Therapeutic drug monitoring of voriconazole in children.伏立康唑的治疗药物监测在儿童中的应用。
Ther Drug Monit. 2012 Feb;34(1):77-84. doi: 10.1097/FTD.0b013e31823f3516.
8
Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.模拟标准剂量抗真菌药物对新体外药代动力学/药效学模型中曲霉菌属的药效学影响。
Antimicrob Agents Chemother. 2012 Jan;56(1):403-10. doi: 10.1128/AAC.00662-11. Epub 2011 Nov 7.
9
Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.氟康唑治疗人工感染烟曲霉的日本鹌鹑（ Coturnix japonica ）的疗效。
Med Mycol. 2010 Mar;48(2):234-44. doi: 10.1080/13693780903008821.
10
Pleural diffusion of voriconazole in a patient with Aspergillus fumigatus empyema thoracis.伏立康唑在一名烟曲霉性脓胸患者中的胸膜扩散情况。
Antimicrob Agents Chemother. 2004 Mar;48(3):1065. doi: 10.1128/AAC.48.3.1065.2004.
引用本文的文献
1
Pharmacokinetic interaction of voriconazole and clarithromycin in Pakistani healthy male volunteers: a single dose, randomized, crossover, open-label study.伏立康唑与克拉霉素在巴基斯坦健康男性志愿者中的药代动力学相互作用：一项单剂量、随机、交叉、开放标签研究。
Front Pharmacol. 2023 Jun 9;14:1134803. doi: 10.3389/fphar.2023.1134803. eCollection 2023.
2
Is It Time for Systematic Voriconazole Pharmacogenomic Investigation for Central Nervous System Aspergillosis?是否到了系统性伏立康唑药物基因组学研究中枢神经系统曲霉病的时候了？
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00705-18. Print 2018 Sep.
3
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.抑酸治疗与感染风险：利弊分析
Clin Drug Investig. 2017 Jul;37(7):587-624. doi: 10.1007/s40261-017-0519-y.
4
Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.CYP2C19*2/*17基因型对异基因造血干细胞移植术后患者伏立康唑不良反应的影响：四例报告
J Cancer Res Clin Oncol. 2017 Jun;143(6):1103-1106. doi: 10.1007/s00432-017-2357-y. Epub 2017 Feb 28.
5
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.曲霉病诊断和管理实践指南：美国感染病学会2016年更新版
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.
6
In vitro study of the variable effects of proton pump inhibitors on voriconazole.质子泵抑制剂对伏立康唑的不同影响的体外研究
Antimicrob Agents Chemother. 2015 Sep;59(9):5548-54. doi: 10.1128/AAC.00884-15. Epub 2015 Jun 29.
7
Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.伏立康唑的治疗药物监测：一例 CYP2C19 活性增高患者的多种药物相互作用案例报告。
AIDS Res Ther. 2014 Aug 4;11:25. doi: 10.1186/1742-6405-11-25. eCollection 2014.
8
CNS Mold Infections.中枢神经系统霉菌感染
Curr Infect Dis Rep. 2013 Oct 13. doi: 10.1007/s11908-013-0376-7.
9
Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.重症监护病房患者和血液恶性肿瘤患者伏立康唑血药浓度不足的潜在因素。
Antimicrob Agents Chemother. 2013 Jul;57(7):3262-7. doi: 10.1128/AAC.00251-13. Epub 2013 Apr 29.
本文引用的文献
1
Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.伏立康唑血药浓度最佳值的调查与阈：描述性统计荟萃分析。
J Infect Chemother. 2012 Aug;18(4):501-7. doi: 10.1007/s10156-011-0363-6. Epub 2012 Jan 11.
2
Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.观察性研究伏立康唑的临床疗效及其与患者血浆浓度的关系。
Antimicrob Agents Chemother. 2011 Oct;55(10):4782-8. doi: 10.1128/AAC.01083-10. Epub 2011 Jul 18.
3
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.临床药物基因组学实施联盟 CYP2C19（细胞色素 P450-2C19）基因型和氯吡格雷治疗指南。
Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29.
4
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.对侵袭性真菌病患者进行伏立康唑治疗药物监测可改善疗效和安全性结果。
Clin Infect Dis. 2008 Jan 15;46(2):201-11. doi: 10.1086/524669.
5
Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.监测伏立康唑血药浓度对于避免造血干细胞移植受者出现治疗不足的血药浓度可能是必要的。
Cancer. 2007 Apr 15;109(8):1532-5. doi: 10.1002/cncr.22568.
6
Voriconazole therapeutic drug monitoring.伏立康唑治疗药物监测。
Antimicrob Agents Chemother. 2006 Apr;50(4):1570-2. doi: 10.1128/AAC.50.4.1570-1572.2006.
7
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.奥美拉唑对伏立康唑稳态药代动力学的影响。
Br J Clin Pharmacol. 2003 Dec;56 Suppl 1(Suppl 1):56-61. doi: 10.1046/j.1365-2125.2003.02000.x.
8
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.伏立康唑与两性霉素B用于侵袭性曲霉病的初始治疗比较
N Engl J Med. 2002 Aug 8;347(6):408-15. doi: 10.1056/NEJMoa020191.
9
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens.伏立康唑静脉给药至口服剂量递增方案后的药代动力学及安全性
Antimicrob Agents Chemother. 2002 Aug;46(8):2546-53. doi: 10.1128/AAC.46.8.2546-2553.2002.
10
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.奥美拉唑和兰索拉唑作为细胞色素P450同工酶抑制剂的评估。
Drug Metab Dispos. 1997 Jul;25(7):853-62.
Zotero 插件